The development and applications of circulating tumour cells, circulating tumour DNA and other emerging biomarkers for early cancer detection

David Sinclair Thomas Junior , Junjie Chai , Yong-Jie Lu

Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002314

PDF (12009KB)
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) :1002314 DOI: 10.37349/etat.2025.1002314
Review
research-article
The development and applications of circulating tumour cells, circulating tumour DNA and other emerging biomarkers for early cancer detection
Author information +
History +
PDF (12009KB)

Abstract

Despite major improvements in cancer treatment, detection, and health promotion, the mortality rates of late-stage cancer remain high. This is a critical issue because a large proportion of cancer mortality is experienced by patients who have late-stage disease at diagnosis. As survival is substantially higher for almost all cancers when diagnosed at an early stage, effective early cancer detection strategies could drastically reduce overall cancer mortality. Advances in various technologies have culminated in the development of liquid biopsies. The tumour biomarkers applied for non- or minimally-invasive cancer detection include tumour cells and their components in bodily fluids, especially peripheral blood for circulating tumour biomarkers. The most well-studied circulating tumour biomarkers in recent years for the early detection of cancer are circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA), with research into other classes rapidly expanding. CTCs and ctDNA have been detected at an early stage in several types of cancer with high specificity, aiding risk stratification and, in some cases, identifying clinically actionable molecular features. Therefore, these circulating biomarkers offer several advantages over the traditional cancer detection methods. Although their limitations are considerable, the evolving evidence suggests they have tremendous potential as tools for early cancer detection. In this review, we evaluate the development and applications of circulating biomarkers for early cancer detection, with a focus on CTCs and ctDNA. We also briefly explore the emerging evidence on extracellular vesicles, circulating proteins and synthetic biomarkers, discuss the limitations of current approaches and provide suggestions to achieve further progress in this setting.

Keywords

Early cancer detection / cancer biomarkers / liquid biopsy / circulating tumour cells (CTCs) / circulating tumour DNA (ctDNA)

Cite this article

Download citation ▾
David Sinclair Thomas Junior, Junjie Chai, Yong-Jie Lu. The development and applications of circulating tumour cells, circulating tumour DNA and other emerging biomarkers for early cancer detection. Exploration of Targeted Anti-tumor Therapy, 2025, 6 (1) : 1002314 DOI:10.37349/etat.2025.1002314

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71: 209-49.

[2]

Cancer fact sheet [Internet]. Geneva: WHO; c2025 [cited 2024 Jul 5]. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer

[3]

Quaresma M, Coleman MP, Rachet B. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: a population-based study. Lancet. 2015; 385: 1206-18.

[4]

Cancer mortality for all cancers combined [Internet]. London: Cancer Research UK; c2022 [cited 2024 Jul 5]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/mortality/all-cancers-combined#heading-One

[5]

Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TM, Myklebust TÅ, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019; 20: 1493-505.

[6]

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023; 73: 17-48.

[7]

Crosby D, Bhatia S, Brindle KM, Coussens LM, Dive C, Emberton M, et al. Early detection of cancer. Science. 2022; 375: eaay9040.

[8]

The Cancer Survival in High-Income Countries (SURVMARK-2) project is part of the second phase of the International Cancer Benchmarking Partnership (ICBP) [Internet]. Lyon: IARC; c2023 [cited 2024 Jul 7]. Available from: https://gco.iarc.fr/survival/survmark/

[9]

Clarke CA, Hubbell E, Kurian AW, Colditz GA, Hartman A, Gomez SL. Projected Reductions in Absolute Cancer-Related Deaths from Diagnosing Cancers Before Metastasis, 2006-2015. Cancer Epidemiol Biomarkers Prev. 2020; 29: 895-902.

[10]

Han X, Yang NN, Nogueira L, Jiang C, Wagle NS, Zhao J, et al. Changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA: a cross-sectional nationwide assessment. Lancet Oncol. 2023; 24: 855-67.

[11]

Guven DC, Sahin TK, Yildirim HC, Cesmeci E, Incesu FGG, Tahillioglu Y, et al. Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality. BMJ Support Palliat Care. 2021; bmjspcare-2021-003301.

[12]

Cancer incidence statistics [Internet]. London: Cancer Research UK; [cited 2024 Jul 7]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence#heading-Zero

[13]

de Bazelaire C, Coffin A, Cohen S, Scemama A, de Kerviler E. Biopsies in oncology. Diagn Interv Imaging. 2014; 95: 647-57.

[14]

Gilson P, Merlin J, Harlé A. Deciphering Tumour Heterogeneity: From Tissue to Liquid Biopsy. Cancers (Basel). 2022; 14: 1384.

[15]

Swift SL, Duffy S, Lang SH. Impact of tumor heterogeneity and tissue sampling for genetic mutation testing: a systematic review and post hoc analysis. J Clin Epidemiol. 2020; 126: 45-55.

[16]

Erdi YE. Limits of Tumor Detectability in Nuclear Medicine and PET. Mol Imaging Radionucl Ther. 2012; 21: 23-8.

[17]

Schiffman JD, Fisher PG, Gibbs P. Early Detection of Cancer: Past, Present, and Future. Am Soc Clin Oncol Educ Book. 2015; 35: 57-65.

[18]

Jonas DE, Reuland DS, Reddy SM, Nagle M, Clark SD, Weber RP, et al. Screening for Lung Cancer With Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021; 325: 971-87.

[19]

Srivastava S, Koay EJ, Borowsky AD, De Marzo AM, Ghosh S, Wagner PD, et al. Cancer overdiagnosis: a biological challenge and clinical dilemma. Nat Rev Cancer. 2019; 19: 349-58.

[20]

Pantel K, Alix-Panabieres C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010; 16: 398-406.

[21]

Herath S, Sadeghi Rad H, Radfar P, Ladwa R, Warkiani M, O’Byrne K, et al. The Role of Circulating Biomarkers in Lung Cancer. Front Oncol. 2022; 11: 801269.

[22]

Pal M, Muinao T, Boruah HPD, Mahindroo N. Current advances in prognostic and diagnostic biomarkers for solid cancers: Detection techniques and future challenges. Biomed Pharmacother. 2022; 146: 112488.

[23]

Perkins GL, Slater ED, Sanders GK, Prichard JG. Serum tumor markers. Am Fam Physician. 2003; 68: 1075-82.

[24]

US Preventive Services Task Force; Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW, et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018; 319: 1901-13.

[25]

Lone SN, Nisar S, Masoodi T, Singh M, Rizwan A, Hashem S, et al. Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol Cancer. 2022; 21: 79.

[26]

Boukovala M, Westphalen CB, Probst V. Liquid biopsy into the clinics: Current evidence and future perspectives. J Liq Biopsy. 2024; 4: 100146.

[27]

Lawrence R, Watters M, Davies CR, Pantel K, Lu Y. Circulating tumour cells for early detection of clinically relevant cancer. Nat Rev Clin Oncol. 2023; 20: 487-500.

[28]

Medina JE, Dracopoli NC, Bach PB, Lau A, Scharpf RB, Meijer GA, et al. Cell-free DNA approaches for cancer early detection and interception. J Immunother Cancer. 2023; 11: e006013.

[29]

Yu D, Li Y, Wang M, Gu J, Xu W, Cai H, et al. Exosomes as a new frontier of cancer liquid biopsy. Mol Cancer. 2022; 21: 56.

[30]

Ding Z, Wang N, Ji N, Chen Z. Proteomics technologies for cancer liquid biopsies. Mol Cancer. 2022; 21: 53.

[31]

Wang W, Rong Z, Wang G, Hou Y, Yang F, Qiu M. Cancer metabolites: promising biomarkers for cancer liquid biopsy. Biomark Res. 2023; 11: 66.

[32]

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-74.

[33]

Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol. 2022; 15: 129.

[34]

Castaneda M, den Hollander P, Kuburich NA, Rosen JM, Mani SA. Mechanisms of cancer metastasis. Semin Cancer Biol. 2022; 87: 17-31.

[35]

Lin D, Shen L, Luo M, Zhang K, Li J, Yang Q, et al. Circulating tumor cells: biology and clinical significance. Signal Transduct Target Ther. 2021; 6: 404.

[36]

Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014; 158: 1110-22.

[37]

Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol. 2013; 31: 539-44.

[38]

Grillet F, Bayet E, Villeronce O, Zappia L, Lagerqvist EL, Lunke S, et al. Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture. Gut. 2017; 66: 1802-10.

[39]

Jolly MK, Somarelli JA, Sheth M, Biddle A, Tripathi SC, Armstrong AJ, et al. Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas. Pharmacol Ther. 2019; 194: 161-84.

[40]

Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001; 414: 105-11.

[41]

Schuster E, Taftaf R, Reduzzi C, Albert MK, Romero-Calvo I, Liu H. Better together: circulating tumor cell clustering in metastatic cancer. Trends Cancer. 2021; 7: 1020-32.

[42]

Szczerba BM, Castro-Giner F, Vetter M, Krol I, Gkountela S, Landin J, et al. Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature. 2019; 566: 553-7.

[43]

Dasgupta A, Lim AR, Ghajar CM. Circulating and disseminated tumor cells: harbingers or initiators of metastasis? Mol Oncol. 2017; 11: 40-61.

[44]

Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012; 148: 349-61.

[45]

Trapp E, Janni W, Schindlbeck C, Jückstock J, Andergassen U, de Gregorio A, et al. ; SUCCESS Study Group. Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. J Natl Cancer Inst. 2019; 111: 380-7.

[46]

Allen-Mersh TG, McCullough TK, Patel H, Wharton RQ, Glover C, Jonas SK. Role of circulating tumour cells in predicting recurrence after excision of primary colorectal carcinoma. Br J Surg. 2007; 94: 96-105.

[47]

Sänger N, Effenberger KE, Riethdorf S, Van Haasteren V, Gauwerky J, Wiegratz I, et al. Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ. Int J Cancer. 2011; 129: 2522-6.

[48]

Mead R, Duku M, Bhandari P, Cree IA. Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. Br J Cancer. 2011; 105: 239-45.

[49]

Anderson TR. A Case of Cancer in Which Cells Similar to Those in the Tumors Were Seen in the Blood after Death. Australas Med J. 1869; 14: 146-7.

[50]

Gold B, Cankovic M, Furtado LV, Meier F, Gocke CD. Do Circulating Tumor Cells, Exosomes, and Circulating Tumor Nucleic Acids Have Clinical Utility? A Report of the Association for Molecular Pathology. J Mol Diagn. 2015; 17: 209-24.

[51]

Nguyen TNA, Huang P, Chu P, Hsieh C, Wu M. Recent Progress in Enhanced Cancer Diagnosis, Prognosis, and Monitoring Using a Combined Analysis of the Number of Circulating Tumor Cells (CTCs) and Other Clinical Parameters. Cancers (Basel). 2023; 15: 5372.

[52]

Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: Clinical impact and future directions. Cancer Lett. 2007; 253: 180-204.

[53]

Li X, Li Y, Shao W, Li Z, Zhao R, Ye Z. Strategies for enrichment of circulating tumor cells. Transl Cancer Res. 2020; 9: 2012-25.

[54]

de Wit S, van Dalum G, Terstappen LW. Detection of Circulating Tumor Cells. Scientifica (Cairo). 2014; 2014: 819362.

[55]

Gertler R, Rosenberg R, Fuehrer K, Dahm M, Nekarda H, Siewert JR. Detection of Circulating Tumor Cells in Blood Using an Optimized Density Gradient Centrifugation. Recent Results Cancer Res. 2003; 162: 149-55.

[56]

Hvichia GE, Parveen Z, Wagner C, Janning M, Quidde J, Stein A, et al. A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells. Int J Cancer. 2016; 138: 2894-904.

[57]

Xu L, Mao X, Imrali A, Syed F, Mutsvangwa K, Berney D, et al. Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System. PLoS One. 2015; 10: e0138032.

[58]

Xu L, Mao X, Grey A, Scandura G, Guo T, Burke E, et al. Noninvasive Detection of Clinically Significant Prostate Cancer Using Circulating Tumor Cells. J Urol. 2020; 203: 73-82.

[59]

Sun Q, Li W, Yang D, Lin PP, Zhang L, Guo H. The Presence of Small-Size Circulating Tumor Cells Predicts Worse Prognosis in Non-Small Cell Lung Cancer Patients. Arch Pathol Lab Med. 2025; 149: 39-49.

[60]

Descamps L, Le Roy D, Deman A. Microfluidic-Based Technologies for CTC Isolation: A Review of 10 Years of Intense Efforts towards Liquid Biopsy. Int J Mol Sci. 2022; 23: 1981.

[61]

Che J, Yu V, Dhar M, Renier C, Matsumoto M, Heirich K, et al. Classification of large circulating tumor cells isolated with ultra-high throughput microfluidic Vortex technology. Oncotarget. 2016; 7: 12748-60.

[62]

O’Shannessy DJ, Davis DW, Anderes K, Somers EB. Isolation of Circulating Tumor Cells from Multiple Epithelial Cancers with ApoStream® for Detecting (or Monitoring) the Expression of Folate Receptor Alpha. Biomark Insights. 2016; 11: 7-18.

[63]

Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, et al. Inertial Focusing for Tumor Antigen-Dependent and -Independent Sorting of Rare Circulating Tumor Cells. Sci Transl Med. 2013; 5: 179ra47.

[64]

Franken B, de Groot MR, Mastboom WJ, Vermes I, van der Palen J, Tibbe AG, et al. Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res. 2012; 14: R133.

[65]

Thery L, Meddis A, Cabel L, Proudhon C, Latouche A, Pierga J, et al. Circulating Tumor Cells in Early Breast Cancer. JNCI Cancer Spectr. 2019; 3: pkz026.

[66]

Jin L, Zhao W, Zhang J, Chen W, Xie T, Wang L, et al. Evaluation of the diagnostic value of circulating tumor cells with CytoSorter® CTC capture system in patients with breast cancer. Cancer Med. 2020; 9: 1638-47.

[67]

Sastre J, Maestro ML, Puente J, Veganzones S, Alfonso R, Rafael S, et al. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol. 2008; 19: 935-8.

[68]

Lu Y, Wang P, Peng J, Wang X, Zhu Y, Shen N. Meta-analysis Reveals the Prognostic Value of Circulating Tumour Cells Detected in the Peripheral Blood in Patients with Non-Metastatic Colorectal Cancer. Sci Rep. 2017; 7: 905.

[69]

Tsai W, You J, Hung H, Hsieh P, Hsieh B, Lenz H, et al. Novel Circulating Tumor Cell Assay for Detection of Colorectal Adenomas and Cancer. Clin Transl Gastroenterol. 2019; 10: e00088.

[70]

Xu L, Mao X, Guo T, Chan PY, Shaw G, Hines J, et al. The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis. Clin Cancer Res. 2017; 23: 5112-22.

[71]

Ankeny JS, Court CM, Hou S, Li Q, Song M, Wu D, et al. Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. Br J Cancer. 2016; 114: 1367-75.

[72]

Zeune LL, Boink YE, van Dalum G, Nanou A, de Wit S, Andree KC, et al. Deep learning of circulating tumour cells. Nat Mach Intell. 2020; 2: 124-33.

[73]

An L, Liu Y, Liu Y. Advancements in Circulating Tumor Cell Detection for Early Cancer Diagnosis: An Integration of Machine Learning Algorithms with Microfluidic Technologies. Biosensors. 2025; 15: 220.

[74]

Svensson C, Hübler R, Figge MT. Automated Classification of Circulating Tumor Cells and the Impact of Interobsever Variability on Classifier Training and Performance. J Immunol Res. 2015; 2015: 573165.

[75]

Hatzidaki E, Iliopoulos A, Papasotiriou I. A Novel Method for Colorectal Cancer Screening Based on Circulating Tumor Cells and Machine Learning. Entropy (Basel). 2021; 23: 1248.

[76]

Svensson C, Krusekopf S, Lücke J, Figge MT. Automated detection of circulating tumor cells with naive Bayesian classifiers. Cytometry A. 2014; 85: 501-11.

[77]

Guo J, Chen Z, Ban YL, Kang Y. Precise Enumeration of Circulating Tumor Cells Using Support Vector Machine Algorithm on a Microfluidic Sensor. IEEE Trans Emerg Top Comput. 2014; 14; 5: 518-25.

[78]

Guo Z, Lin X, Hui Y, Wang J, Zhang Q, Kong F. Circulating Tumor Cell Identification Based on Deep Learning. Front Oncol. 2022; 12: 843879.

[79]

Park J, Ha SM, Kim J, Song JW, Hyun KA, Kamiya T, et al. Classification of circulating tumor cell clusters by morphological characteristics using convolutional neural network-support vector machine. Sensor Actuat B-Chem. 2024; 40: 134896.

[80]

Crook T, Leonard R, Mokbel K, Thompson A, Michell M, Page R, et al. Accurate Screening for Early-Stage Breast Cancer by Detection and Profiling of Circulating Tumor Cells. Cancers (Basel). 2022; 14: 3341.

[81]

Limaye S, Chowdhury S, Rohatgi N, Ranade A, Syed N, Riedemann J, et al. Accurate prostate cancer detection based on enrichment and characterization of prostate cancer specific circulating tumor cells. Cancer Med. 2023; 12: 9116-27.

[82]

Murlidhar V, Reddy RM, Fouladdel S, Zhao L, Ishikawa MK, Grabauskiene S, et al. Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early-Stage Lung Cancers. Cancer Res. 2017; 77: 5194-206.

[83]

Mego M, Karaba M, Minarik G, Benca J, Silvia J, Sedlackova T, et al. Circulating Tumor Cells With Epithelial-to-mesenchymal Transition Phenotypes Associated With Inferior Outcomes in Primary Breast Cancer. Anticancer Res. 2019; 39: 1829-37.

[84]

Diamantopoulou Z, Castro-Giner F, Schwab FD, Foerster C, Saini M, Budinjas S, et al. The metastatic spread of breast cancer accelerates during sleep. Nature. 2022; 607: 156-62.

[85]

Saucedo-Zeni N, Mewes S, Niestroj R, Gasiorowski L, Murawa D, Nowaczyk P, et al. A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int J Oncol. 2012; 41: 1241-50.

[86]

Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017; 17: 223-38.

[87]

Volckmar A, Sültmann H, Riediger A, Fioretos T, Schirmacher P, Endris V, et al. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications. Genes Chromosomes Cancer. 2018; 57: 123-39.

[88]

Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977; 37: 646-50.

[89]

Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev. 1994; 3: 67-71.

[90]

Taniguchi K, Uchida J, Nishino K, Kumagai T, Okuyama T, Okami J, et al. Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas. Clin Cancer Res. 2011; 17: 7808-15.

[91]

Sun K, Jiang P, Chan KCA, Wong J, Cheng YKY, Liang RHS, et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci U S A. 2015; 112: E5503-12.

[92]

Stejskal P, Goodarzi H, Srovnal J, Hajdúch M, van’t Veer LJ, Magbanua MJM. Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance. Mol Cancer. 2023; 22: 15.

[93]

Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018; 10: eaat4921.

[94]

Wang W, Kong P, Ma G, Li L, Zhu J, Xia T, et al. Characterization of the release and biological significance of cell-free DNA from breast cancer cell lines. Oncotarget. 2017; 8: 43180-91.

[95]

Marcuello M, Vymetalkova V, Neves RPL, Duran-Sanchon S, Vedeld HM, Tham E, et al. Circulating biomarkers for early detection and clinical management of colorectal cancer. Mol Aspects Med. 2019; 69: 107-22.

[96]

Sánchez-Herrero E, Serna-Blasco R, Robado de Lope L, González-Rumayor V, Romero A, Provencio M. Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis. Front Oncol. 2022; 12: 943253.

[97]

Kustanovich A, Schwartz R, Peretz T, Grinshpun A. Life and death of circulating cell-free DNA. Cancer Biol Ther. 2019; 20: 1057-67.

[98]

Rapisuwon S, Vietsch EE, Wellstein A. Circulating biomarkers to monitor cancer progression and treatment. Comput Struct Biotechnol J. 2016; 14: 211-22.

[99]

Davidson CJ, Zeringer E, Champion KJ, Gauthier M, Wang F, Boonyaratanakornkit J, et al. Improving the Limit of Detection for Sanger Sequencing: A Comparison of Methodologies for KRAS Variant Detection. Biotechniques. 2012; 53: 182-8.

[100]

Elazezy M, Joosse SA. Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management. Comput Struct Biotechnol J. 2018; 16: 370-8.

[101]

Danesi R, Lo YMD, Oellerich M, Beck J, Galbiati S, Re MD, et al. What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology?-Considerations on pre-analytical aspects by the IFCC workgroup cfDNA. Clin Chim Acta. 2021; 520: 168-71.

[102]

Lee JS, Kim M, Seong MW, Kim HS, Lee YK, Kang HJ. Plasma vs. serum in circulating tumor DNA measurement: characterization by DNA fragment sizing and digital droplet polymerase chain reaction. Clin Chem Lab Med. 2020; 58: 527-32.

[103]

Tan SC, Yiap BC. DNA, RNA, and Protein Extraction: The Past and The Present. J Biomed Biotechnol. 2009; 2009: 574398.

[104]

Lehle S, Emons J, Hack CC, Heindl F, Hein A, Preuß C, et al. Evaluation of automated techniques for extraction of circulating cell-free DNA for implementation in standardized high-throughput workflows. Sci Rep. 2023; 13: 373.

[105]

Malentacchi F, Pizzamiglio S, Verderio P, Pazzagli M, Orlando C, Ciniselli CM, et al. Influence of storage conditions and extraction methods on the quantity and quality of circulating cell-free DNA (ccfDNA): the SPIDIA-DNAplas External Quality Assessment experience. Clin Chem Lab Med. 2015; 53: 1935-42.

[106]

Yaghoubi Naei V, Bordhan P, Mirakhorli F, Khorrami M, Shrestha J, Nazari H, et al. Advances in novel strategies for isolation, characterization, and analysis of CTCs and ctDNA. Ther Adv Med Oncol. 2023; 15: 17588359231192401.

[107]

Campos CDM, Gamage SST, Jackson JM, Witek MA, Park DS, Murphy MC, et al. Microfluidic-based solid phase extraction of cell free DNA. Lab Chip. 2018; 18: 3459-70.

[108]

Jin CE, Koo B, Lee TY, Han K, Lim SB, Park IJ, et al. Simple and Low-Cost Sampling of Cell-Free Nucleic Acids from Blood Plasma for Rapid and Sensitive Detection of Circulating Tumor DNA. Adv Sci (Weinh). 2018; 5: 1800614.

[109]

Diehl F, Li M, He Y, Kinzler KW, Vogelstein B, Dressman D. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods. 2006; 3: 551-9.

[110]

Olmedillas-López S, García-Arranz M, García-Olmo D. Current and Emerging Applications of Droplet Digital PCR in Oncology. Mol Diagn Ther. 2017; 21: 493-510.

[111]

Dang DK, Park BH. Circulating tumor DNA: current challenges for clinical utility. J Clin Invest. 2022; 132:e154941.

[112]

Tébar-Martínez R, Martín-Arana J, Gimeno-Valiente F, Tarazona N, Rentero-Garrido P, Cervantes A. Strategies for improving detection of circulating tumor DNA using next generation sequencing. Cancer Treat Rev. 2023; 119: 102595.

[113]

Lin C, Liu X, Zheng B, Ke R, Tzeng C. Liquid Biopsy, ctDNA Diagnosis through NGS. Life (Basel). 2021; 11: 890.

[114]

Li L, Sun Y. Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges. MedComm (2020). 2024; 5: e766.

[115]

Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Sci Transl Med. 2014; 6: 224ra24.

[116]

Zill OA, Banks KC, Fairclough SR, Mortimer SA, Vowles JV, Mokhtari R, et al. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients. Clin Cancer Res. 2018; 24: 3528-38.

[117]

Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017; 9: eaan2415.

[118]

Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, et al. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol. 2018; 36: 1631-41.

[119]

Chen X, Gole J, Gore A, He Q, Lu M, Min J, et al. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nat Commun. 2020; 11: 3475.

[120]

Locke WJ, Guanzon D, Ma C, Liew YJ, Duesing KR, Fung KYC, et al. DNA Methylation Cancer Biomarkers: Translation to the Clinic. Front Genet. 2019; 10: 1150.

[121]

Nicholson BD, Oke J, Virdee PS, Harris DA, O’Doherty C, Park JE, et al. Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study. Lancet Oncol. 2023; 24: 733-43.

[122]

Fitzgerald RC, di Pietro M, O’Donovan M, Maroni R, Muldrew B, Debiram-Beecham I, et al. Cytosponge-trefoil factor 3 versus usual care to identify Barrett’s oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial. Lancet. 2020; 396: 333-44.

[123]

Klein EA, Richards D, Cohn A, Tummala M, Lapham R, Cosgrove D, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021; 32: 1167-77.

[124]

Schrag D, Beer TM, McDonnell CH 3rd, Nadauld L, Dilaveri CA, Reid R, et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023; 402: 1251-60.

[125]

Oke JL, Brown SJ, Senger C, Welch HG. Deceptive measures of progress in the NHS long-term plan for cancer: case-based vs. population-based measures. Br J Cancer. 2023; 129: 3-7.

[126]

Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021; 397: 2182-93.

[127]

Feng X, Zahed H, Onwuka J, Callister MEJ, Johansson M, Etzioni R, et al. Cancer Stage Compared With Mortality as End Points in Randomized Clinical Trials of Cancer Screening: A Systematic Review and Meta-Analysis. JAMA. 2024; 331: 1910-7.

[128]

Bronkhorst AJ, Holdenrieder S. The changing face of circulating tumor DNA (ctDNA) profiling: Factors that shape the landscape of methodologies, technologies, and commercialization. Med Genet. 2023; 35: 201-35.

[129]

van der Leest P, Schuuring E. Critical Factors in the Analytical Work Flow of Circulating Tumor DNA-Based Molecular Profiling. Clin Chem. 2024; 70: 220-33.

[130]

Thierry AR, El Messaoudi S, Gahan PB, Anker P, Stroun M. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 2016; 35: 347-76.

[131]

Bredholt G, Mannelqvist M, Stefansson IM, Birkeland E, Bø TH, Øyan AM, et al. Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses. Oncotarget. 2015; 6: 39676-91.

[132]

Chung DC, Gray DM 2nd, Singh H, Issaka RB, Raymond VM, Eagle C, et al. A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening. N Engl J Med. 2024; 390: 973-83.

[133]

van Niel G, D’Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018; 19: 213-28.

[134]

Paskeh MDA, Entezari M, Mirzaei S, Zabolian A, Saleki H, Naghdi MJ, et al. Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. J Hematol Oncol. 2022; 15: 83.

[135]

Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D. Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis. Cancer Cell. 2016; 30: 836-48.

[136]

Marar C, Starich B, Wirtz D. Extracellular vesicles in immunomodulation and tumor progression. Nat Immunol. 2021; 22: 560-70.

[137]

Muralidharan-Chari V, Clancy JW, Sedgwick A, D’Souza-Schorey C. Microvesicles: mediators of extracellular communication during cancer progression. J Cell Sci. 2010; 123: 1603-11.

[138]

Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018; 560: 382-6.

[139]

Daassi D, Mahoney KM, Freeman GJ. The importance of exosomal PDL1 in tumour immune evasion. Nat Rev Immunol. 2020; 20: 209-15.

[140]

Peinado H, Alečković M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012; 18: 883-91.

[141]

Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol. 2015; 17: 816-26.

[142]

Liu J, Qin J, Liang L, Zhang X, Gao J, Hao Y, et al. Novel insights into the regulation of exosomal PD-L1 in cancer: From generation to clinical application. Eur J Pharmacol. 2024; 979: 176831.

[143]

Hoshino A, Costa-Silva B, Shen T, Rodrigues G, Hashimoto A, Tesic Mark M, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015; 527: 329-35.

[144]

Cheng S, Li Y, Yan H, Wen Y, Zhou X, Friedman L, et al. Advances in microfluidic extracellular vesicle analysis for cancer diagnostics. Lab Chip. 2021; 21: 3219-43.

[145]

Hinestrosa JP, Kurzrock R, Lewis JM, Schork NJ, Schroeder G, Kamat AM, et al. Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test. Commun Med (Lond). 2022; 2: 29.

[146]

Zhang Y, Liu W, Zhang H, Sun B, Chen T, Hu M, et al. Extracellular vesicle long RNA markers of early-stage lung adenocarcinoma. Int J Cancer. 2023; 152: 1490-500.

[147]

Barker AD, Alba MM, Mallick P, Agus DB, Lee JSH. An Inflection Point in Cancer Protein Biomarkers: What was and What’s Next. Mol Cell Proteomics. 2023; 22: 100569.

[148]

Wik L, Nordberg N, Broberg J, Björkesten J, Assarsson E, Henriksson S, et al. Proximity Extension Assay in Combination with Next-Generation Sequencing for High-throughput Proteome-wide Analysis. Mol Cell Proteomics. 2021; 20: 100168.

[149]

Budnik B, Amirkhani H, Forouzanfar MH, Afshin A. Novel proteomics-based plasma test for early detection of multiple cancers in the general population. BMJ Oncol. 2024; 3: e000073.

[150]

Kirkpatrick JD, Warren AD, Soleimany AP, Westcott PMK, Voog JC, Martin-Alonso C, et al. Urinary detection of lung cancer in mice via noninvasive pulmonary protease profiling. Sci Transl Med. 2020; 12: eaaw0262.

[151]

Marcus PM. Assessment of cancer screening: a primer [Internet]. Bethesda (MD): National Cancer Institute (US); 2019 [cited 2024 Dec 11]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK550212/

[152]

Faster Diagnosis Framework and the Faster Diagnostic Standard [Internet]. Leeds: NHS; [cited 2024 Dec 11]. Available from: https://www.england.nhs.uk/cancer/faster-diagnosis/#fds

[153]

Erridge S, Lyratzopoulos G, Renzi C, Millar A, Lee R. Rapid Diagnostic Centres and early cancer diagnosis. Br J Gen Pract. 2021; 71: 487-8.

[154]

Jung AW, Holm PC, Gaurav K, Hjaltelin JX, Placido D, Mortensen LH, et al. Multi-cancer risk stratification based on national health data: a retrospective modelling and validation study. Lancet Digit Health. 2024; 6: e396-406.

[155]

Early Diagnosis Data Hub [Internet]. London: Cancer Research UK; [cited 2024 Dec 11]. Available from: https://crukcancerintelligence.shinyapps.io/EarlyDiagnosis/

[156]

Levelling up: what does it mean for the less survivable cancers in England? [Internet]. London: Merck Sharpe & Dohme; Less Survivable Cancers Taskforce; [cited 2024 Dec 11]. Available from: https://lesssurvivablecancers.org.uk/wp-content/uploads/2024/12/MSD-Levelling-up-what-does-it-mean-for-the-less-survivable-cancers-in-England.pdf

[157]

Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018; 359: 926-30.

[158]

Sefrioui D, Blanchard F, Toure E, Basile P, Beaussire L, Dolfus C, et al. Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours. Br J Cancer. 2017; 117: 1017-25.

[159]

Nicolò E, Gianni C, Pontolillo L, Serafini MS, Munoz-Arcos LS, Andreopoulou E, et al. Circulating tumor cells et al.: towards a comprehensive liquid biopsy approach in breast cancer. Transl Breast Cancer Res. 2024; 5: 10.

[160]

Moon SM, Kim J, Kim SK, Kim S, Kwon H, Bae J, et al. Clinical Utility of Combined Circulating Tumor Cell and Circulating Tumor DNA Assays for Diagnosis of Primary Lung Cancer. Anticancer Res. 2020; 40: 3435-44.

PDF (12009KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉